AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Follow-Up Questions
Qui est le CEO de AIM ImmunoTech Inc ?
Mr. Thomas Equels est le President de AIM ImmunoTech Inc, il a rejoint l'entreprise depuis 2008.
Quelle est la performance du prix de l'action AIM ?
Le prix actuel de AIM est de $1.87, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de AIM ImmunoTech Inc ?
AIM ImmunoTech Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de AIM ImmunoTech Inc ?
La capitalisation boursière actuelle de AIM ImmunoTech Inc est de $5.0M
Est-ce que AIM ImmunoTech Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 2 analystes ont établi des notations d'analystes pour AIM ImmunoTech Inc, y compris 1 achat fort, 3 achat, 1 maintien, 0 vente et 1 vente forte
